Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis

Immune checkpoint inhibitors (ICPI), such as ipilimumab [anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody] and nivolumab or pembrolizumab [anti-programmed cell death protein-1 (PD-1) antibodies], improve survival in several cancer types. Since inhibition of CTLA-4 or PD-1 leads to non-selecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergqvist, Viktoria, Hertervig, Erik, Gedeon, Peter, Kopljar, Marija, Griph, Håkan, Kinhult, Sara, Carneiro, Ana, Marsal, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406433/
https://www.ncbi.nlm.nih.gov/pubmed/28204866
http://dx.doi.org/10.1007/s00262-017-1962-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406433/
https://www.ncbi.nlm.nih.gov/pubmed/28204866
http://dx.doi.org/10.1007/s00262-017-1962-6

Ejemplares similares